Novalis Biotech is an early stage venture capital fund in life sciences. Novalis focuses on capital light business models and platform technology. Novalis Biotech is an early stage venture capital investor in life sciences. Our investment ideas focus on the interaction between bio-informatics and life sciences. We strongly believe in applying innovative information technology to advance prevention, diagnosis, or treatment of diseases. As an early stage private equity/venture capital fund, we are a dynamic and flexible player not restricting ourselves to specific fields of expertise, but open to discuss any proposition in the field of life-sciences. We welcome innovative concepts in healthcare and aim to support their development already at the state of incorporation. Focus areas are: innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health.
Ghent, Belgium
Founded in 2018
1-10 Employees
Working industry
Biotechnology
Type of company
Manufacturer
Ownership structure
Public Company
Locations
1 Headquarter
Number of products
16 Products
Specialised areas
Biotechnology, Life Science, Venture Capital
Novalis Biotechnology Incubation offers a wide range of products and services
Product
Portfolio | Novalis Biotech Incubation
Go to product >
Product
Rarity Bioscience | Novalis Biotech Incubation
Go to product >
Product
Modality.AI | Novalis Biotech Incubation
Go to product >
Product
Doc.ai | Novalis Biotech Incubation
Go to product >
Product
Enzyre | Novalis Biotech Incubation
Go to product >
Product
C-mo Medical Solutions | Novalis Biotech Incubation
Go to product >
Product
BioLizard | Novalis Biotech Incubation
Go to product >
Product
Epify | Novalis Biotech Incubation
Go to product >
Novalis Biotechnology Incubation operates in 1 country around the world
Get an overview of the locations of Novalis Biotechnology Incubation
Location
Country
State
City
Headquarter
Belgium
East Flanders
Ghent
Some frequent questions that have been asked about Novalis Biotechnology Incubation
Where is Novalis Biotechnology Incubation located?
The company headquarter of Novalis Biotechnology Incubation is located in Ghent, East Flanders, Belgium. It's worth noting, that the company may have more locations
How many employees does Novalis Biotechnology Incubation approximately have?
As of the latest available information Novalis Biotechnology Incubation has around 1-10 employees worldwide.
When was Novalis Biotechnology Incubation founded?
Novalis Biotechnology Incubation was founded in 2018
In which industries does Novalis Biotechnology Incubation mainly work?
The company Novalis Biotechnology Incubation has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Novalis Biotechnology Incubation
Novaquest Capital Management
Raleigh, United States
11-50 Employees
2010
With its unique global platform, NovaQuest Capital Management promotes the late-stage development of life-saving drugs in order to reduce the cost of healthcare, address unmet medical needs, improve safety, and enhance overall quality of life. Late-stage PRODUCT FINANCE™ investments in global biopharmaceutical products.
Pivotal bioVenture Partners
San Francisco, United States
1-10 Employees
2017
Established in 2017, we are a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe. We specialize in venture building in the life sciences industry, partnering with innovative healthcare companies in the Greater China region. We focus on capturing investment opportunities with publicly traded life sciences companies that are looking to scale and grow.
Nan Fung Life Sciences
San Francisco, United States
1-10 Employees
2017
Established in 2017, we are a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe. We specialize in venture building in the life sciences industry, partnering with innovative healthcare companies in the Greater China region. We focus on capturing investment opportunities with publicly traded life sciences companies that are looking to scale and grow.
NIVALIS Group
Villaz, Switzerland
11-50 Employees
2002
Nivalis Group cultivates and invests in high-tech startups that develop industry-changing technologies. We invest, because entrepreneurs do not have unlimited resources. Nivalis Group invests financial capital, smart money and human capital in high-tech startups that develop new and unique technologies for the next generation engineering industries. We primarily focus on early stage Seed and Series A investments. We are entrepreneurs and we know that it takes more than cash to go from proof of concept to a minimum viable product and a successful market launch.
Novartis Venture Fund
Basel, Switzerland
11-50 Employees
1996
We specialize in investments ranging from USD 5-10 million, primarily focusing on Seed and Series A stage companies. With a focus on those companies developing novel therapeutics and platforms in the biotechnology and biopharma space, the NVF ambition is to address unmet patient needs. We manage over USD 750 million in committed capital and more than 40 portfolio companies across North America and Europe.
NovalGen
London, United Kingdom
11-50 Employees
2019
NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond. Our mission is to create life-enhancing and curative new treatments for people with cancer. Headquartered in London, UK, NovalGen was formed in 2019. NovalGen is guided by our core set of values. The culture of NovalGen reflects these values and they help guide our decisions. NovalGen’s first pipeline product is a proprietary first in class bispecific T cell engager therapies that can safely harness the immune system to fight a wide range of cancers. We are changing the paradigm of cancer therapy with our immunotherapy technology.
Topics which have been searched by others and may be interesting for you:
